Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka Reports Interim Phase 2b/c Data Indicating New Compound May Shorten Tuberculosis
Details : OPC-167832 (quabodepistat) is a potent and orally active dprE1 inhibitor, which is being evaluated in combination with delamanid & bedaquiline for the treatment of pulmonary tuberculosis.
Product Name : OPC-167832
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2024
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
J&J’s Sirturo for Tuberculosis Receives Full US, EU Approvals
Details : Sirturo (bedaquiline) is an approved ATP synthase inhibitor. It is given orally for the treatment in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary MDR-TB.
Product Name : Sirturo
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 07, 2024
Lead Product(s) : Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delamanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This program is evaluating two novel drug regimens comprising five antibacterial agents—bedaquiline, delamanid, pretomanid, quabodepistat (formerly known as OPC-167832), and sutezolid.
Product Name : Deltyba
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : Delamanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sirturo (bedaquiline) is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary MDR-TB.
Product Name : Sirturo
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 11, 2023
Lead Product(s) : Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The PAN-TB collaboration is a first-of-its-kind effort to accelerate development of a drug regimen capable of treating all forms of TB, and identifying promising regimens for further development including OPC-167832.
Product Name : OPC-167832
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 17, 2022
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $17.8 million
Deal Type : Funding
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-TB Combo
Details : The grant will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson’s bedaquiline, for patients with drug-susceptible pulmonary tuberculosis (DS-TB).
Product Name : OPC-167832
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 08, 2021
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $17.8 million
Deal Type : Funding
Lead Product(s) : Pretomanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
Details : Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Product Name : PA-824
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 09, 2021
Lead Product(s) : Pretomanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves New Pediatric Formulation of SIRTURO® (bedaquiline) as Part of Combination Therapy
Details : SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB).
Product Name : Sirturo
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 27, 2020
Lead Product(s) : Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pretomanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive.
Product Name : PA-824
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 08, 2020
Lead Product(s) : Pretomanid,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable